What if the one injection that is helping you lose weight and manage diabetes also protect you from cancer? That's the surprising promise emerging from a new study on GLP-1 drugs, drugs already drawing attention for their ability to battle obesity and regulate blood sugar. Now scientists have discovered a potential new advantage: a much reduced risk of cancers related to obesity.

While the global use of GLP-1 agonists such as Saxenda and Byetta is gaining speed, this research unlocks a thrilling new era in preventive care. But just how do such medications function and why could they be protecting us against cancer?

After once being touted as miracle drugs for treating obesity and type 2 diabetes, GLP-1 medications such as Saxenda and Byetta are now uncovering a new benefit: a reduced risk of cancer. New research in the journal eClinicalMedicine identifies that these initial weight-loss medications may have more to their credit than just reducing waistlines—they can cut the risk of developing obesity-linked cancers by a dramatic 41%.

This finding has the potential to change forever the way that we think about the wider ramifications of GLP-1 treatments, particularly in a world where metabolic diseases are closely associated with cancer susceptibility. But why might this new benefit exist? And how do these drugs actually work?

What Are GLP-1 Drugs and How Do They Work?

GLP-1 agonists (glucagon-like peptide-1 receptor agonists) are a type of drug that mimics the effect of an endogenous hormone involved in the modulation of appetite, blood glucose levels, and digestion. Initially approved for the treatment of type 2 diabetes, they've become very popular due to their capacity to cause weight loss by reducing hunger and slowing gastric emptying.

Drugs such as liraglutide (Saxenda) and exenatide (Byetta) are usually given through subcutaneous injection. Newer forms, including semaglutide (Ozempic) and tirzepatide (Zepbound), have greater efficacy in weight loss and metabolic control, although they were not part of this specific study.

GLP-1 acts via a cascade of hormonal action:

• It triggers the release of insulin from the pancreas, lowering blood sugar.
• It inhibits the release of glucagon, a hormone that increases blood sugar.
• It reduces the rate at which the stomach empties following meals.

Perhaps most importantly for managing weight, it sends satiety messages to the brain to make people feel fuller for longer.

Missing Link Between Cancer Risk and Obesity

Both type 2 diabetes and obesity are firmly established as risk factors for many forms of cancer, such as breast, colon, uterine, pancreatic, and liver cancer. This can be explained by the chronic inflammation, insulin resistance, and hormonal imbalance that accompany excess fat stores.

For their new study, scientists from Clalit Health Services in Tel Aviv, Israel, analyzed electronic health records of more than 6,300 adults age 24 and above. Everyone involved had both type 2 diabetes and obesity and received either GLP-1 medication or weight-loss surgery between 2010 and 2018. The group was followed through to December 2023 to record cancer diagnoses.

During a median follow-up of 7.5 years, approximately 300 individuals developed cancer of the obesity type—predominantly breast (26%), colon (16%), and uterus (15%).

GLP-1 vs. Surgery

Although bariatric surgery has been the obesity treatment gold standard for decades—and was in turn found to lower cancer risk—scientists discovered obesity-associated cancers were equal in both the surgery and GLP-1 groups. This was unexpected because surgery tends to induce greater and more immediate weight loss.

Still, additional statistical examination found that the GLP-1 medications offered a 41% lower risk of cancerous developments than surgery indicated that their anti-cancer benefit might extend beyond weight loss alone.

Reason Behind the Anti-Cancer Effect

According to co-lead researcher Dr. Dror Dicker, who heads the Obesity Clinic at Hasharon Hospital-Rabin Medical Center, the anti-cancer effects of GLP-1 drugs likely stem from multiple mechanisms. “Reducing inflammation, improving insulin sensitivity, and altering cellular growth pathways may all play a role,” he noted in a news release.

While more recent, more powerful GLP-1 medications such as Ozempic and Zepbound were not included in the study, researchers are convinced they may provide even stronger protective effects. However, additional long-term studies are necessary to determine their impacts on cancers that are not related to obesity.

Can It Change Cancer Treatment?

This new evidence indicates a paradigm shift of foundational importance in the way we think about metabolic health interventions. GLP-1 medications could soon be hailed not merely as weight-loss supplements or treatments for diabetes but as prevention against one of the world's most dreaded illnesses.

Nevertheless, prudence is still advisable. Long-term experience with these drugs is lacking, and their side effects, including nausea, gastrointestinal upset, and possible hazards for thyroid tumors, need to be weighed. A boxed warning is now placed on the list of the FDA for some GLP-1 drugs for thyroid C-cell tumors, although this has so far been seen most commonly in animal models.

With the worldwide obesity epidemic on the rise, so is the need to know how drugs such as GLP-1 agonists can change not only waistlines, but also long-term health endpoints. The notion that a single class of medication might lower the risk of cancer in addition to managing blood glucose and reducing appetite is revolutionary.

Additional research, particularly with next-generation GLP-1 drugs, will be necessary to more fully investigate and validate these benefits but for the time being, this study introduces an exhilarating and promising new chapter at the nexus of cancer prevention and obesity treatment.

Warning has been issued in Plymouth due to an increase in drug overdose which have been linked to substances like heroin or pregabalin. Naloxone Advocates Plymouth, also known as NAP issued the warning for people to take "extra care". NAP is a community interest company or a CIC, which is made of volunteers who work to reduce drug-related deaths in Plymouth.

Warning On Drug Overdose: What Is It?

On March 2, NAP shared a Facebook post, where the NAP spokesperson said: "A quick heads up for people in Plymouth/ We have recently seen more overdoses than usual linked to substances that slow breathing (such as heroin or pregabalin). We want people to be aware so they can take extra care."

Signs Of Someone Who Is Overdosing

• Being unconscious
• Slow breathing or not breathing
• Loud snoring
• Choking or gurgling sounds
• Blue lips

NAP also said if someone becomes unwell, one must immediately call 999, and place the person in the recovery position if they are breathing.

Read: Jannik Sinner Drug Suspension: Why Wimbledon Winner Was Banned – The Clostebol Drug Test Controversy Explained

What To Do If Someone Has Overdosed On Drugs?

NAP also noted emergency antidote, as reported by Plymouth Herald too, in the event of an overdose of heroin or other opiated or opioids. NAP noted that even if you are unaware of what the unwell person has takes, the antidote "will not harm them, and sometimes drugs contain opioids even when they are not sold as such". NAP said one can administer naloxone as an antidote.

NAP also asked the person to stay with the unwell person for 20 minutes or until help arrives as the person could go back into overdose once naloxone wears off.

If the person is not breathing, one should immediately call 999 and start CPR, noted NAP.

What Is Naloxone? The Antidote That Works On Drug Overdose

As per the National Institute on Drug Abuse, NIH, US, naloxone is a medicine that rapidly reverses an opioid overdose. It is an opioid antagonist. This means that it attaches to opioid receptors and reverses and blocks the effects of other opioids. Naloxone can quickly restore normal breathing to a person if their breathing has slowed or stopped because of an opioid overdose. But, naloxone has no effect on someone who does not have opioids in their system, and it is not a treatment for opioid use disorder.

It should be given to any person who shows signs of an opioid overdose or when an overdose is suspected. It could be administered through nasal spray or injected through the muscle, under the skin or into the veins.

The National Institute on Drug Abuse notes that families and loved ones could carry naloxone with them if they know someone in their family struggles with drug abuse. However, they can ask pharmacists or health care provider on how to administer the antidote.

However one must not that it works in the body for only 30 to 90 minutes, whereas some opioids could stay longer than that. This is why it is important to call for help. Furthermore, people given naloxone must be observed and monitored even after the last dose of naloxone to make sure their breathing do not slow down.

The US Centers for Disease Control and Prevention (CDC) has stated that an unvaccinated person who traveled to the US from Europe spread measles to 17 others in the country last year.

In a paper published in The Journal of Infectious Diseases, the CDC highlighted the case of an unvaccinated traveler who arrived at the Denver International Airport in Colorado in May 2025.

The person traveled with a fever, persistent cough, cold-like symptoms, and conjunctivitis (“pink eye”). He stayed overnight in a hotel and then boarded another flight to North Dakota. A day later, the person developed a rash.

“The index case was in an unvaccinated adult. Aircraft contact investigations identified 135 exposed domestic travelers. Fifteen secondary cases were identified among people exposed during the international (5) and domestic (3) flights, and at the airport (7),” the CDC said in the paper.

“Two tertiary case-patients were also identified. Five of the secondary case-patients had at least one documented prior measles vaccination,” it added.

The 2025 US Measles Outbreak

While measles was declared eliminated in the US in 2000, and sporadic outbreaks were controlled quickly, falling vaccination rates, especially during the COVID-19 pandemic, raise the risk of larger, harder-to-contain outbreaks.

This was further compounded by the anti-vaccine stance of President Donald Trump and his Health Secretary Robert F Kennedy Jr.

As per the CDC, a total of 2,281 confirmed measles cases were reported in the US in 2025. In 2026, the agency reported 10 new outbreaks, with more than 1,000 measles cases confirmed to date. More than 90 percent cases each year occurred in the unvaccinated.

Air Travel Increases Measles Spread

Recently, two passengers from India infected with measles landed in Auckland, New Zealand, via Singapore Airlines.

The Straits Times quoted Associate Professor Lim Poh Lian, group director of the Communicable Disease Agency’s (CDA) Communicable Disease Program, who noted that the individuals developed symptoms only while onboard the flight from Singapore to Auckland.

“Measles transmission may occur during travel. Travelers with fever and other overt signs of transmissible illness, such as coughing or malaise, should be strongly encouraged to delay travel while symptomatic,” the US CDC said.

Vaccination Key To Tackling Measles

Measles is a highly infectious disease characterized by the three Cs:

• Cough
• Coryza or runny nose
• Conjunctivitis or red and watery eyes

It easily spreads from one infected person to another through breaths, coughs, or sneezes and could cause severe disease, complications, and even death.

Even though a safe and cost-effective vaccine is available, in 2024, there were an estimated 95,000 measles deaths globally, mostly among unvaccinated or under-vaccinated children under the age of 5 years, according to the World Health Organization (WHO).

The CDC recommends that all travelers aged 6 months or older get vaccinated before international travel.

Sacred Games actress Rajshri Deshpande today informed of being diagnosed with grade 1 breast cancer and shared her journey of recovery.

In an Instagram post, the 43-year-old actress announced being diagnosed with the Infiltrating ductal carcinoma (NOS) -- the most common breast cancer type, accounting for roughly 80 percent of cases.

Importantly, the actress known for her work in Trial by Fire and Manto said that the deadly disease was detected during routine screening, initiating the road to early recovery.

“As you’re reading this, it means I’ve finally found the courage to tell my parents that I have been diagnosed with Infiltrating ductal carcinoma (NOS), a grade 1 Breast cancer. Now it’s time you all know,” the Instagram post read.

“We fortunately caught this early in a routine checkup, which gave us a fighting chance,” she added.

Rajshri called her treatment with ‘tons of tests and surgery” “a rollercoaster ride”.

“Trust me, it was everyone’s love and warmth that carried me through,” she said, while thanking her fans and her parents whose “faces after surgery melted my fears into unbreakable strength”.

“With everyone’s support, I feel am ready to take on the world,” Rajshri said, adding that she “is recovering beautifully and soon heading home from the hospital”.

What Is Infiltrating Ductal Carcinoma (IDC)

Also known as Invasive ductal carcinoma, the cancer occurs when abnormal cells growing in the lining of the milk ducts change and invade breast tissue beyond the walls of the duct.

Breast ducts are the passageways where milk from the milk glands (lobules) flows to the nipple.

Common symptoms of IDC include

• A lump or thickening in the breast or armpit area
• Changes in the size, shape, or appearance of the breast
• Nipple changes, such as inversion, discharge, or scaling
• Breast pain or discomfort
• Skin changes on the breast, like redness or dimpling

Key risk factors of IDC include

• Genetic mutations such as BRCA1 and BRCA2 gene mutations, and a family history of breast cancer
• Higher levels of estrogen
• Prolonged exposure to ionising radiation
• smoking
• excessive alcohol consumption
• obesity
• a sedentary lifestyle

Rising Early-Onset Cancers in women

The recent The Lancet Oncology study mentioned a rise in new cases in women aged 20-54 years (up 29 percent) since 1990.

Recently, American actress Christy Carlson Romano announced a positive cancer screening test.

Cancer is everywhere, said Romano, 41, in a tearful video on social media platform Instagram.

A 2025 study by Duke Cancer Institute in the US revealed that for women younger than 50, the risk of developing cancer is 82 percent higher than that of men, up from 51 percent in 2022.

The 2025 annual report from the American Cancer Society (ACS) also showed that cancer rates in young and middle-aged women are rising past those of men in the same age group, but especially among women under age 50.

Importance of Early Screening

As with Rajshri, catching cancer in its early stages can help individuals experience less severe symptoms, minimize discomfort, and improve overall quality of life.

Detection of cancer at an early stage can boost survival rates. It can increase the chances of successful treatment.

Common screening methods include

• Physical examination of your breasts by your doctor
• Mammography
• Breast ultrasound
• Breast magnetic resonance imaging (MRI)